drugset
drugset / Trial / NCT02835508

Pharmacokinetic Study of JNJ-56021927 When Taken Orally as Tablet Formulation in Healthy Male Japanese Participants

NCT02835508 ↗

Phase 1 Completed 18 enrolled Janssen Pharmaceutical K.K.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to assess the safety and Pharmacokinetic (PK) profile of JNJ-56021927 and its active metabolite JNJ-56142060 after single-dose administration of 60 milligram (mg), 120 mg, and 240 mg JNJ-56021927 as the tablet formulation in healthy male Japanese participants.

Timeline

Start
2016-06
Primary completion
2016-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Apalutamide Small molecule 60 mg Oral
Subject Apalutamide Small molecule 120 mg Oral
Subject Apalutamide Small molecule 240 mg Oral

Indications

No indication recorded.